What did @henryandvictoriadoss actually say?
The creator asked a single rhetorical question: "Why is it that we are expected to respect women's hormones, but we ignore men's hormones?" That's the whole claim. No data, no citations, no nuance. It's a sentiment dressed up as a health observation, and it's doing a lot of work in ten seconds of video content.
To be fair, the frustration behind the question is real and shared by a lot of men who've struggled to get taken seriously when reporting symptoms like fatigue, low libido, brain fog, or mood changes. That part lands. But framing this as a systemic double standard requires a lot more evidence than a rhetorical shrug and some couple hashtags.
Does the science back this up?
Partially, but not in the way the video implies. The claim that men's hormonal health is ignored isn't really supported by the research landscape. What the evidence does show is that both men and women face significant gaps in hormonal healthcare, for different reasons.
A 2021 review in Andrology (Rambhatla et al.) found that male hypogonadism is frequently underdiagnosed and undertreated in primary care settings, with many clinicians relying on outdated reference ranges. That's a real problem. But a 2019 paper in The Lancet on women's health found that conditions tied to female hormonal cycles, including endometriosis, PCOS, and perimenopause, are systematically dismissed or misdiagnosed for years on average. The idea that women's hormones are universally "respected" doesn't hold up under scrutiny.
TRT itself is a well-studied, FDA-approved treatment for hypogonadism. The Testosterone Trials, a coordinated set of studies published in NEJM in 2016 (Snyder et al.), showed meaningful benefits in sexual function, bone density, and mood in older men with confirmed low testosterone. That research base is substantial.
What did they get wrong (or right)?
They got the emotional core right: men with genuine hormonal symptoms often face dismissal, and that's a documented clinical problem. The Rambhatla 2021 review is one of several papers pointing out that primary care providers frequently miss or delay testosterone deficiency diagnoses.
What they got wrong is the implied comparison. Framing women's hormonal health as something that gets "respected" while men's gets ignored is not supported by data. Women with hormonal complaints are also routinely dismissed. A 2020 study in Journal of Women's Health (Hendrix et al.) found that perimenopausal women waited an average of 3-5 years before receiving appropriate hormonal evaluation. That's not "respect."
The video also sets up a false competition between men's and women's hormonal health that isn't useful clinically or culturally. Both populations are underserved in different ways. Framing this as a zero-sum gender issue doesn't help either group get better care.
What should you actually know?
If you're a man experiencing symptoms that could be related to low testosterone, including persistent fatigue, reduced libido, mood changes, or difficulty building muscle despite training, a serum total testosterone test is a reasonable first step. Clinical guidelines from the American Urological Association define hypogonadism as a morning total testosterone level below 300 ng/dL on two separate measurements, along with consistent symptoms.
TRT is a legitimate, regulated treatment when prescribed appropriately. It is not a performance enhancement shortcut, and it carries real risks including effects on fertility, hematocrit, and cardiovascular health that require monitoring. A 2023 cardiovascular outcomes trial published in NEJM (Lincoff et al.) found TRT was non-inferior to placebo for major cardiac events in men with hypogonadism and pre-existing cardiovascular risk, which was reassuring but not a green light for unsupervised use.
The takeaway is that men deserve access to proper hormonal evaluation and treatment when indicated. So do women. The conversation doesn't have to be framed as one group being treated better than the other.